Cannabis Report: Record profits, lawsuits, and acquisitions, oh my!
Click here for the full story.
1 | Xebra Brands announces letter of intent to acquire CBD e-commerce company BSK Holdings
2 | Organigram Global shares recording of its OG investor session
3 | Canopy Growth sued for securities law violations
4 | 4Front provides update on management cease trade order application
Top Cannabis Stocks Apr. 18 to Apr. 24, 2025
1. T.TLRY | 5,784 views | Tilray Brands Inc.
2. T.LABS | 5,766 views | Medipharm Labs Corp.
3. T.CURA | 4,238 views | Curaleaf Holdings Inc.
4. T.WEED | 3,254 views | Canopy Growth Corp.
5. T.OGI | 593 views | Organigram Holdings Inc.
6. C.TGIF | 545 views | 1933 Industries Inc. Inc.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
13-08-2025
- Cision Canada
MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States
MediPharm Labs holds unique US Food and Drug Administration (FDA) site registration in relation to the manufacturing and release of pharmaceutical cannabis products. MediPharm is the only US FDA Audited purpose-built commercial cannabis facility in Canada. One of a handful globally. The possible rescheduling of cannabis in the US opens new opportunities for MediPharm in categories where the Company maintains a competitive advantage. TORONTO, Aug. 13, 2025 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to share insights on its US FDA site registration in relation to the possible rescheduling of cannabis in the United States. Communication from the US Federal Government and various media reports have indicated that the administration is reviewing the rescheduling of cannabis federally in the US. Speculation is that this will mean changing the classification of cannabis from a Schedule I drug to a Schedule III drug. What rescheduling means for cannabis in the United States: The rescheduling would recognize the medical benefits of cannabis at a federal level. Schedule III registration would drastically expand the possibility for US based research on medical cannabis products. Current, Schedule I drug classification puts controls in place that make it difficult for this research to be funded and undertaken today. This would open up the possibility for the US to expand special access medical cannabis programs, like those in Canada, Australia and Germany. How MediPharm is best positioned in the event of rescheduling cannabis in the US: MediPharm has gone through the complex process of a foreign drug manufacturing site registration with the US FDA. Following a week-long inspection by an FDA representative MediPharm was granted the ability to produce, label, test and release drugs. MediPharm has filed a drug master file (DMF) with the US FDA for CBD active pharmaceutical ingredient (API). The active ingredient file is required for drug manufacturers to source CBD for late-stage clinical trials and finished dose products. MediPharm has already shipped medical cannabis API and cannabis products to the US for research, including a National Institutes of Health (NIH) funded clinical trial. This delivery required the US FDA site registration and import permits issued by the US DEA. Upon possible rescheduling of cannabis, MediPharm Labs holds existing licences and expertise to serve the anticipated expansion of US based research and possible new medical special access programs. To MediPharm's understanding no other publicly listed cannabis-focused company in North America has this stack of licensing, including an FDA inspected cannabis facility. It takes years of regulatory and quality activities to achieve this suite of licensing, and enable clinical research with pharmaceutical cannabis. MediPharm Labs continues to maintain their top tier pharmaceutical licenses and registrations to continue its position as a leader in the global cannabis market. The Company will continue to monitor changes in the US scheduling of cannabis to serve researchers and patients with quality cannabis API and products. About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial scale domestic Good Manufacturing License for the extraction of multiple natural cannabinoids. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. In 2023, MediPharm acquired VIVO Cannabis Inc. which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical PTY and Beacon Medical GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions. Cautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, possible rescheduling of cannabis in the United States, the expansion of US based research on medical cannabis products, the expansion of special access medical cannabis programs in the US, opportunities for future clinical research opportunities, future marketable pharmaceutical products, and future Canadian and international commercial products that leverage MediPharm's unique pharmaceutical expertise. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; MediPharm's competitive licensing and FDA site inspection and registration; and other factors discussed in MediPharm Labs' filings, available on the SEDAR+ website at There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
Cision Canada
05-08-2025
- Cision Canada
Charlotte's Web 2025 Second Quarter Earnings Call and Webcast Notice
LOUISVILLE, Colo., Aug. 5, 2025 /CNW/ - (TSX: CWEB) (OTC: CWBHF) Charlotte's Web Holdings, Inc. (" Charlotte ' s Web" or the " Company") a botanical wellness innovation company and the market leader in cannabidiol (CBD) hemp extract wellness products, will report its 2025 second quarter results prior to market open on August 13, 2025. A conference call to review the results is scheduled for the same day at 11:00 A.M. Eastern Time. There are three ways to join the call: Register and enter your phone number at to receive an instant automated call back, or Dial 1-646-357-8785 or 1-800-836-8184 approximately 10 minutes before the conference call, or Listen to the live webcast online. Earnings Call Replay A recording of the call will be available through August 20, 2025. To listen to a replay of the earnings call please dial 1- 646-517-4150 or 1-888-660-6345 and provide conference replay ID 22439#. A webcast of the call will also be accessible through the investor relations section of the Company's website for an extended period of time. Subscribe to Charlotte's Web investor news. About Charlotte's Web Holdings, Inc. Charlotte's Web Holdings, Inc., a Certified B Corporation headquartered in Louisville, Colorado, is a botanical wellness innovation company and a market leader in hemp extract wellness that includes Charlotte's Web whole-plant full-spectrum CBD extracts as well as broad-spectrum CBD and cannabinoid isolates. The Company's hemp extracts have naturally occurring botanical compounds including cannabidiol ("CBD"), CBN, CBC, CBG, THC, terpenes, flavonoids, and other beneficial compounds. Charlotte's Web product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, calming, exercise recovery, immunity), CBN gummies, hemp-derived THC microdose gummies, functional mushroom gummies, CBD capsules, CBD topical creams, and lotions, as well as CBD pet products for dogs. Through its substantially vertically integrated business model, Charlotte's Web maintains stringent control over product quality and consistency with analytic testing from soil to shelf for quality assurance. Charlotte's Web products are distributed to retailers and healthcare practitioners throughout the U.S.A. and are available online through the Company's website at
Canada News.Net
27-07-2025
- Canada News.Net
THC beverages bite into beer sales, alcohol giants plan counter
NEW YORK CITY, New York: As cannabis-infused drinks grow in popularity and take over retail shelf space once dominated by beer and spirits, major alcohol companies are preparing for a potential pivot into the emerging category. THC drinks—infused with the psychoactive compound found in marijuana—are being sold legally across many U.S. states when derived from hemp, a federally legal crop. These hemp-based beverages are increasingly available in liquor stores, convenience shops, and supermarkets, offering a legal workaround to traditional dispensary restrictions. While leading alcohol companies have largely sat out this boom, a shift is underway. Founders of cannabis beverage brands, ingredient suppliers, and drink manufacturers told Reuters that some big players are now exploring entry points into the market, prompted by declining alcohol sales and growing consumer interest in alternatives. Constellation Brands has been studying hemp-based cannabis drinks, according to a source familiar with its plans. Pernod Ricard recently met with Brez, a THC beverage brand, to discuss a possible investment. "They did not invest now but are circling," said Brez founder Aaron Nosbisch. Pernod declined to comment. U.S. alcohol sales have cooled since their pandemic-era spike. Beer volumes dropped nearly 6 percent through May, while spirits and wine declined by 5.6 percent and 9 percent, respectively. Public health warnings linking alcohol to cancer have also pressured the industry. Meanwhile, hemp-based THC drinks are booming. The market is expected to top US$1 billion in sales this year and quadruple by 2028, according to Euromonitor. Companies like Tilray are already moving in. Its THC seltzers, sold through existing beer distributors, are now available in 13 states. "There's not a real leader... and that's what we look to do," said CEO Irwin Simon. Legacy alcohol brands are cautiously experimenting. Boston Beer, known for Sam Adams, is testing a hemp-based version of its THC tea brand Teapot in the U.S., following its rollout in Canada. "This is a source of growth for our organization, flat out," said Paul Weaver, who leads the company's cannabis division. But challenges remain. State regulations vary widely. California banned hemp-based drinks last year, while other states have imposed taxes or restrictions. Senator Mitch McConnell recently proposed federal limits on intoxicating hemp products to keep them away from children. Big brewers have also faced past setbacks. In 2022, Anheuser-Busch exited its cannabis joint venture in Canada, and Molson Coors shut its CBD beverage division in the U.S. that same year. Despite this, retail enthusiasm is strong. Liquor stores report that THC beverages are driving higher margins than beer or spirits. At Top Ten Liquors in Minnesota, they now account for 15 percent of business and could soon rival wine in sales. "The soccer mom has really embraced the category," said CEO Jon Halper. Distributors, too, are seeing the shift. Southern Horizon Logistics now sells more hemp-based drinks than wine and spirits. Best Brands CEO Ryan Moses said growth in this segment helped avoid layoffs by reallocating staff. For consumers like Josh Goldberg, who swapped beer for THC seltzers two years ago, the appeal is simple: "It replaces the physical act of drinking with drinking something else."
